POPPK MODELING OF Q2M IM RPV LA FOR MANAGING DOSING INTERRUPTIONS IN HIV-1 PATIENTS
Long-acting rilpivirine (RPV LA) is intended for coadministration with cabotegravir long-acting (CAB LA) as a complete 2-drug injectable regimen for HIV-1 treatment. Eight-weekly RPV LA plus CAB LA was noninferior to 4-weekly RPV LA plus CAB LA in maintaining HIV-1 suppression (ATLAS-2M; Overton TE et al. CROI 2020 Abstract 34). Every 2 months (Q2M) RPV…